Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin

NCT00396916 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT00396916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00396916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Value of Novel Imaging Modality, Hybrid PET/CT, Using F18-Flurodeoxyglucose(FDG) in the Assessment of Cancer Patients. Impact of PET/CT on Clinical Management of Patients With Rising Tumor Markers and no Other Evidence of Disease and in Patients With Metastatic Cancer of Unknown Origin
Lead sponsor
Rambam Health Care Campus
Phase
Not applicable
Overall status
Completed
Start date
December 31, 2004
Completion date
Not reported
Enrollment
45
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer